Journal article · 2023 · Open access

Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

Fabrizio Calisti, Michael Tocco, Yongcai Mao, Andrei Pikalov, ROBERT S. GOLDMAN

CNS Spectrums, 28(2), 248–249 · Published 1 April 2023 · DOI 10.1017/s1092852923001876

Open PDFView at the publisherCite this paper

In brief

“Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies” is a 2023 journal article by Fabrizio Calisti and 4 co-authors, published in CNS Spectrums. OpenAlex counts 0 citations as of 20 November 2026. It is open access: the full text is free to read at CNS Spectrums.

Citations
0
Authors
5

Abstract

INTRODUCTION: Earlier onset of schizophrenia, which occurs more commonly in males, is characterized by greater illness severity, chronicity, and functional impairment with a less favorable prognosis than later-onset schizophrenia. The aim of this pooled analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents (13-17 years) and young adults (18-25 years). METHODS: The 2 pooled studies used similar designs and outcome measures. Patients (13-25 years) with schizophrenia completed an initial double-blind 6-week trial of lurasidone (40 and 80 mg/d), and (80 and 160 mg/d) in the young adult trial. In the open-label long-term trials, adolescent patients were treated with 20-80 mg/d of lurasidone, and adults were treated with 40-160 mg/d of lurasidone. Efficacy was evaluated based on the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Scale (CGI-S). RESULTS: The safety population consisted of 306 patients (mean age, 16.2 years; 208 patients (68.0%) who completed 12 months of treatment; 8.2% discontinued by 12 months due to an adverse event. Mean (SD) change in the PANSS total score from extension Baseline to Months 6 and 12 was -11.8 (13.9) and -15.3 (15.0), respectively (OC); and mean (SD) change in the CGI-S score was -0.8 (1.0) and -1.0 (1.1), respectively (OC). The most frequent adverse events were headache (17.6%), anxiety (11.4%), schizophrenia (9.8%), and nausea (9.8). No clinically meaningful changes were observed in weight, metabolic parameters, or prolactin. CONCLUSIONS: In adolescents and young adults with schizophrenia, treatment with lurasidone was generally well-tolerated and effective. Long-term treatment was associated with continued reduction in symptoms of schizophrenia. Long-term treatment was associated with minimal effects on weight, metabolic parameters, and prolactin. FUNDING: Angelini Pharma S.p.A. and Sunovion Pharmaceuticals Inc.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Calisti, F., Tocco, M., Mao, Y., Pikalov, A., & GOLDMAN, R. S. (2023). Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies. CNS Spectrums, 28(2), 248–249. https://doi.org/10.1017/s1092852923001876

MLA 9

Calisti, Fabrizio, et al. “Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies.” CNS Spectrums, vol. 28, no. 2, 2023, pp. 248–249. https://doi.org/10.1017/s1092852923001876.

Chicago

Calisti, Fabrizio, Michael Tocco, Yongcai Mao, Andrei Pikalov, and ROBERT S. GOLDMAN. 2023. “Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies.” CNS Spectrums 28 (2): 248–249. https://doi.org/10.1017/s1092852923001876.

Harvard

Calisti, F. et al. (2023) ‘Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies’, CNS Spectrums, 28(2), pp. 248–249. doi:10.1017/s1092852923001876.

IEEE

F. Calisti, M. Tocco, Y. Mao, A. Pikalov, and R. S. GOLDMAN, “Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies,” CNS Spectrums, vol. 28, no. 2, pp. 248–249, 2023, doi: 10.1017/s1092852923001876.

BibTeX

@article{calisti2023long,
  title     = {{Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies}},
  author    = {Calisti, Fabrizio and Tocco, Michael and Mao, Yongcai and Pikalov, Andrei and GOLDMAN, ROBERT S.},
  journal   = {CNS Spectrums},
  year      = {2023},
  volume    = {28},
  number    = {2},
  pages     = {248--249},
  doi       = {10.1017/s1092852923001876},
  url       = {https://doi.org/10.1017/s1092852923001876}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • lurasidone
  • schizophrenia
  • adolescents
  • young adults
  • long-term treatment
  • antipsychotic safety
  • antipsychotic efficacy
  • adverse events

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Calisti, F., Tocco, M., Mao, Y., Pikalov, A., & GOLDMAN, R. S. (2023). Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies. CNS Spectrums, 28(2), 248–249. https://doi.org/10.1017/s1092852923001876

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CNS Spectrums: sign in and open the PDF from this page.

Who wrote this paper?

Fabrizio Calisti, Michael Tocco, Yongcai Mao, Andrei Pikalov, ROBERT S. GOLDMAN.

What is the DOI of this paper?

10.1017/s1092852923001876, permanently at https://doi.org/10.1017/s1092852923001876. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.